Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
BALLOONING administrative and research and development expenses caused Catalist-listed QT Vascular's net loss for the quarter ended June to widen, from US$11.4 million to US$13.5 million even as revenue tripled. For the second quarter, revenue rose from US$1.03 million to US$3.23 million.